Direct blood fluorescence signal intensity of neutrophils (NEU-SFL): A predictive marker of death in hospitalized COVID-19 patients?
COVID-19
NETosis
fluorescence signal intensity
immunothrombosis
neutrophil
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
10
2022
accepted:
07
12
2022
entrez:
9
1
2023
pubmed:
10
1
2023
medline:
10
1
2023
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is a respiratory disease triggered by immunopathological mechanisms that cause excessive inflammation and leukocyte dysfunction. Neutrophils play a critical role in the innate immunity and are able to produce neutrophil extracellular traps (NETs: NETosis process) to combat infections. Some NETs markers are increased in patients who died from COVID-19. Recently, the neutrophil fluorescence variable (NEU-SFL), available on certain automated complete blood count (CBC) analyzers, has been correlated with NET formation and may reflect NETosis in patients. Here we evaluate whether NEU-SFL measured after admission of COVID-19 patients is associated with in-hospital survival or death. 1,852 patients admitted for severe COVID-19 at Nîmes University Hospital in 2021 were retrospectively included in the study: 1,564 who survived the hospital stay and 288 who did not. The NEU-SFL was obtained on the Sysmex™ XN-10 Non-survivors presented higher NEU-SFL values. NEU-SFL values above the 4th quartile were independently associated with a 2.88-fold risk of death. Furthermore, the difference of NEU-SFL values between the first and the last available data during hospitalization revealed that a decrease in NEU-SFL was associated to survivors and vice versa. Our study reinforces the role of neutrophils and NETosis in the pathophysiology and prognosis of COVID-19. Further studies combining NEU-SFL with other NETosis markers could improve the management of COVID-19 patients.
Identifiants
pubmed: 36619613
doi: 10.3389/fmed.2022.1062112
pmc: PMC9812562
doi:
Banques de données
ClinicalTrials.gov
['NCT05413824']
Types de publication
Journal Article
Langues
eng
Pagination
1062112Informations de copyright
Copyright © 2022 Fortier, Chea, Aïn, Loyens, Boudemaghe, Gris and Bouvier.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
Clin Infect Dis. 2022 Feb 11;74(3):479-489
pubmed: 33988226
Shock. 2017 Mar;47(3):313-317
pubmed: 27488091
Front Immunol. 2022 Mar 02;13:838011
pubmed: 35309344
Int J Infect Dis. 2021 May;106:155-159
pubmed: 33781906
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
Thromb Res. 2019 Nov;183:153-158
pubmed: 31678710
Pak J Med Sci. 2022 Jan-Feb;38(1):219-226
pubmed: 35035429
J Thromb Haemost. 2020 May;18(5):1233-1234
pubmed: 32291954
Blood. 2020 Jul 23;136(4):489-500
pubmed: 32492712
J Thromb Haemost. 2018 Jun 8;:
pubmed: 29883046
Thromb Res. 2022 Feb;210:94-103
pubmed: 35042062
Dis Markers. 2021 Nov 17;2021:4361844
pubmed: 34840629
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
J Thromb Haemost. 2020 Jul;18(7):1559-1561
pubmed: 32302453
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Front Immunol. 2022 Mar 17;13:851497
pubmed: 35371025
BMC Infect Dis. 2021 Aug 21;21(1):855
pubmed: 34418980
Crit Care Med. 2016 Nov;44(11):e1132-e1136
pubmed: 27441905
Natl Sci Rev. 2020 Sep;7(9):1414-1418
pubmed: 34192086